Bio-Thera Solutions
Bio-Thera Solutions
Explore linked clinical trials.9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT06341114 | |
| Evaluate the Safety, Tolerability of BAT6026 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT06094179 | |
| A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders | Optic Neuromyelitis Spectrum Disease | Active, not recruiting | Phase 2 | 2026-10-02 | NCT06044350 | |
| A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors | Advanced Solid Tumors | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-30 | NCT06376136 | |
| A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-09-02 | NCT07180862 | |
| Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | Recruiting | Phase 3 | 2026-04-07 | NCT07515079 | |
| A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, focal segmental glomerulosclerosis, glomerulonephritis, kidney disorder, minimal change disease, nephritis, nephrosis, urinary system disorder | Recruiting | Phase 2 / Phase 3 | 2026-04-03 | NCT07499700 | |
| Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-02-09 | NCT05620017 | |
| BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 / Phase 3 | 2025-02-10 | NCT06123884 |